ACADIA Pharmaceuticals Stock Forecast, Price & News

ACADIA Pharmaceuticals (NASDAQ:ACAD) Frequently Asked Questions

Is ACADIA Pharmaceuticals a buy right now?

18 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for ACADIA Pharmaceuticals in the last twelve months. There are currently 12 hold ratings and 6 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "hold" ACADIA Pharmaceuticals stock. A hold rating indicates that analysts believe investors should maintain any existing positions they have in ACAD, but not buy additional shares or sell existing shares.
View analyst ratings for ACADIA Pharmaceuticals or view top-rated stocks.

How has ACADIA Pharmaceuticals' stock been impacted by Coronavirus (COVID-19)?

ACADIA Pharmaceuticals' stock was trading at $36.87 on March 11th, 2020 when Coronavirus (COVID-19) reached pandemic status according to the World Health Organization. Since then, ACAD shares have decreased by 48.3% and is now trading at $19.07.
View which stocks have been most impacted by COVID-19.

When is ACADIA Pharmaceuticals' next earnings date?

ACADIA Pharmaceuticals is scheduled to release its next quarterly earnings announcement on Wednesday, February 23rd 2022.
View our earnings forecast for ACADIA Pharmaceuticals.

How were ACADIA Pharmaceuticals' earnings last quarter?

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD) issued its quarterly earnings data on Monday, November, 8th. The biopharmaceutical company reported ($0.09) EPS for the quarter, topping the Zacks' consensus estimate of ($0.26) by $0.17. The biopharmaceutical company had revenue of $131.61 million for the quarter, compared to analysts' expectations of $127.77 million. ACADIA Pharmaceuticals had a negative trailing twelve-month return on equity of 32.74% and a negative net margin of 40.38%. ACADIA Pharmaceuticals's revenue was up 9.2% on a year-over-year basis. During the same period last year, the company posted ($0.54) earnings per share.
View ACADIA Pharmaceuticals' earnings history.

What guidance has ACADIA Pharmaceuticals issued on next quarter's earnings?

ACADIA Pharmaceuticals updated its FY 2021 earnings guidance on Monday, November, 29th. The company provided earnings per share guidance of for the period. The company issued revenue guidance of $480 million-$500 million, compared to the consensus revenue estimate of $490.42 million.

What price target have analysts set for ACAD?

18 analysts have issued twelve-month price objectives for ACADIA Pharmaceuticals' stock. Their forecasts range from $18.00 to $57.00. On average, they anticipate ACADIA Pharmaceuticals' share price to reach $27.39 in the next twelve months. This suggests a possible upside of 43.7% from the stock's current price.
View analysts' price targets for ACADIA Pharmaceuticals or view top-rated stocks among Wall Street analysts.

Who are ACADIA Pharmaceuticals' key executives?

ACADIA Pharmaceuticals' management team includes the following people:

• Stephen R. Davis, Chief Executive Officer & Director (LinkedIn Profile)
• Srdjan R. Stankovic, President (LinkedIn Profile)
• Brendan P. Teehan, Chief Operating Officer, EVP & Head-Commercial
• Mark Schneyer, Chief Financial & Business Officer
• Bob Mischler, Senior VP-Strategy & Technology Operations

What is Steve Davis' approval rating as ACADIA Pharmaceuticals' CEO?

8 employees have rated ACADIA Pharmaceuticals CEO Steve Davis on Glassdoor.com. Steve Davis has an approval rating of 88% among ACADIA Pharmaceuticals' employees.

Who are some of ACADIA Pharmaceuticals' key competitors?

Some companies that are related to ACADIA Pharmaceuticals include Maravai LifeSciences (MRVI), Ono Pharmaceutical (OPHLF), Dr. Reddy's Laboratories (RDY), Teva Pharmaceutical Industries (TEVA), Bausch Health Companies (BHC), United Therapeutics (UTHR), CureVac (CVAC), Ascendis Pharma A/S (ASND), Legend Biotech (LEGN), Evotec (EVTCY), Jazz Pharmaceuticals (JAZZ), Grifols (GRFS), Biohaven Pharmaceutical (BHVN), Arrowhead Pharmaceuticals (ARWR) and Mirati Therapeutics (MRTX).
View all of ACAD's competitors.

What other stocks do shareholders of ACADIA Pharmaceuticals own?

Based on aggregate information from My MarketBeat watchlists, some companies that other ACADIA Pharmaceuticals investors own include Micron Technology (MU), NVIDIA (NVDA), Gilead Sciences (GILD), Sarepta Therapeutics (SRPT), Pfizer (PFE), Tesla (TSLA), Alibaba Group (BABA), Amarin (AMRN), Advanced Micro Devices (AMD) and Exelixis (EXEL).

What is ACADIA Pharmaceuticals' stock symbol?

ACADIA Pharmaceuticals trades on the NASDAQ under the ticker symbol "ACAD."

Who are ACADIA Pharmaceuticals' major shareholders?

ACADIA Pharmaceuticals' stock is owned by a variety of retail and institutional investors. Top institutional investors include BlackRock Inc. (6.32%), Geode Capital Management LLC (1.26%), Janus Henderson Group PLC (1.21%), Artisan Partners Limited Partnership (0.89%), Nordea Investment Management AB (0.77%) and The Manufacturers Life Insurance Company (0.64%). Company insiders that own ACADIA Pharmaceuticals stock include Austin D Kim, Austin D Kim, Bros Advisors Lp Baker, Elena Ridloff, James M Daly, Laura Brege, Michael J Yang, Srdjan R Stankovic, Srdjan R Stankovic and Stephen Davis.
View institutional ownership trends for ACADIA Pharmaceuticals.

Which major investors are selling ACADIA Pharmaceuticals stock?

ACAD stock was sold by a variety of institutional investors in the last quarter, including Frontier Capital Management Co. LLC, Millennium Management LLC, Skandinaviska Enskilda Banken AB publ , Geode Capital Management LLC, Caption Management LLC, Citadel Advisors LLC, Jane Street Group LLC, and California State Teachers Retirement System. Company insiders that have sold ACADIA Pharmaceuticals company stock in the last year include Austin D Kim, Elena Ridloff, Michael J Yang, Srdjan R Stankovic, and Stephen Davis.
View insider buying and selling activity for ACADIA Pharmaceuticals or view top insider-selling stocks.

Which major investors are buying ACADIA Pharmaceuticals stock?

ACAD stock was bought by a variety of institutional investors in the last quarter, including Nordea Investment Management AB, Goldman Sachs Group Inc., Voloridge Investment Management LLC, Natixis, Balyasny Asset Management LLC, Alliancebernstein L.P., Duality Advisers LP, and Squarepoint Ops LLC.
View insider buying and selling activity for ACADIA Pharmaceuticals or or view top insider-buying stocks.

How do I buy shares of ACADIA Pharmaceuticals?

Shares of ACAD can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is ACADIA Pharmaceuticals' stock price today?

One share of ACAD stock can currently be purchased for approximately $19.07.

How much money does ACADIA Pharmaceuticals make?

ACADIA Pharmaceuticals has a market capitalization of $3.07 billion and generates $441.76 million in revenue each year. The biopharmaceutical company earns $-281.58 million in net income (profit) each year or ($1.20) on an earnings per share basis.

How many employees does ACADIA Pharmaceuticals have?

ACADIA Pharmaceuticals employs 601 workers across the globe.

What is ACADIA Pharmaceuticals' official website?

The official website for ACADIA Pharmaceuticals is www.acadia-pharm.com.

Where are ACADIA Pharmaceuticals' headquarters?

ACADIA Pharmaceuticals is headquartered at 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130.

How can I contact ACADIA Pharmaceuticals?

ACADIA Pharmaceuticals' mailing address is 3611 VALLEY CENTRE DRIVE SUITE 300, SAN DIEGO CA, 92130. The biopharmaceutical company can be reached via phone at (858) 558-2871, via email at [email protected], or via fax at 858-558-2872.